🇺🇸 FDA
Patent

US 8293800

Quinone derivative 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone for the treatment of primary progressive multiple sclerosis

granted A61KA61K31/122A61P

Quick answer

US patent 8293800 (Quinone derivative 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone for the treatment of primary progressive multiple sclerosis) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Oct 18 2032 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Oct 23 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 18 2032 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
12
CPC classes
A61K, A61K31/122, A61P, A61P25/00, A61P37/00